SCHEMBL6849795

SCHEMBL6849795

Nc1nccc(Nc2cccc(-c3cncc(OCC(N)Cc4c[nH]c5ccccc45)c3)c2)n1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 19/20 0.85
PRKACA P17612 3/20 0.64
PRKACG P22612 3/20 0.64
PRKACB P22694 3/20 0.64
PRKCG P05129 2/20 0.64
CDK1 P06493 2/20 0.64
SRC P12931 2/20 0.64
CSNK2A2 P19784 2/20 0.64
MAPK1 P28482 2/20 0.64
AKT2 P31751 2/20 0.64
CSNK2B P67870 2/20 0.64
CSNK2A1 P68400 2/20 0.64
PRKCE Q02156 2/20 0.64
AKT3 Q9Y243 2/20 0.64
DAPK3 O43293 1/20 0.64
PRKD3 O94806 1/20 0.64
MAP4K4 O95819 1/20 0.64
PIM1 P11309 1/20 0.64
FLT1 P17948 1/20 0.64
GRK5 P34947 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6855809 0.92 AKT1 (1.00) AKT1PRKACAPRKACGPRKACBPRKCG
SCHEMBL6849748 0.87 AKT1 (1.00) AKT1PRKACAPRKACGPRKACBPRKCG
SCHEMBL6853321 0.84 AKT1 (0.62) AKT1PRKACAPRKCGCDK1AKT2
SCHEMBL6853323 0.84 AKT1 (0.62) AKT1PRKACAPRKCGCDK1AKT2
SCHEMBL6855167 0.83 AKT1 (1.00) AKT1PRKACAPRKACGPRKACBPRKCG
SCHEMBL6849889 0.83 AKT1 (0.70) AKT1PRKACAPRKACGPRKACBPRKCG
SCHEMBL6857885 0.81 AKT1 (0.78) AKT1PRKACAPRKACGPRKACBPRKCG
SCHEMBL6932395 0.81 AKT1 (0.78) AKT1PRKACAPRKACGPRKACBPRKCG
SCHEMBL6857881 0.81 AKT1 (0.78) AKT1PRKACAPRKACGPRKACBPRKCG
SCHEMBL6857813 0.81 AKT1 (1.00) AKT1AKT2AKT3PRKD3PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831175-B2 Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine ABBOTT LABORATORIES 2004-12-14 US claimed
US-20030199511-A1 Kinase inhibitors ABBVIE INC. 2003-10-23 US claimed
US-20030187026-A1 Kinase inhibitors ABBOTT LABORATORIES 2003-10-02 US claimed
US-6831175-B2 Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine ABBOTT LABORATORIES 2004-12-14 US disclosed
EP-1463505-A2 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER Abbott Laboratories (US) 2004-10-06 EP disclosed
US-20030199511-A1 Kinase inhibitors ABBVIE INC. 2003-10-23 US disclosed
US-20030187026-A1 Kinase inhibitors ABBOTT LABORATORIES 2003-10-02 US disclosed
WO-2003051366-A2 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER ABBOTT LABORATORIES (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187026-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 AKT1 119/4885PRKACA 27/4885PRKACG 37/4885
US-20030199511-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 AKT1 119/4885PRKACA 27/4885PRKACG 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.